BCL2 and osteosarcoma: Recent studies have highlighted TYK2 can act as an oncogene, with TYK2 activation increasing STAT1 phosphorylation and the expression of BCL-2 in T-cell acute lymphoblastic Leukemia and osteosarcoma [48, 49].